For the first time in published literature, Le Bonheur Children’s Hospital and University of Tennessee Health Science Center (UTHSC) researchers showed that a variety of white blood cells known as eosinophils modify the respiratory barrier during influenza A (IAV) infection, according to a recent paper in the journal Cells. This research could have implications in understanding SARS-CoV-2 (COVID-19) infection in asthmatic patients.
The Le Bonheur/UTHSC study found that eosinophils immunomodulate airway epithelial cells during IAV infection, helping to neutralize the virus and protect the airway. The study was led by University of Tennessee Health Science Center Postdoctoral Fellow Meenakshi Tiwary, PhD, from the lab of Director of the Pediatric Asthma Research Program and Plough Foundation Chair of Excellence in Pediatrics, Amali Samarasinghe, PhD, in collaboration with Robert Rooney, PhD, assistant professor of pediatrics at the University of Tennessee Health Science Center and director of the Biorepository and Integrative Genomics Initiative at Le Bonheur, and Swantje Liedmann, PhD, a postdoctoral fellow at St. Jude Children’s Research Hospital.
“We examined eosinophil responses to influenza A virus during the early phase of infection and found that eosinophils exhibit multiple functions as active mediators of antiviral host defense,” said Samarasinghe. “These include virus neutralization, trafficking to draining lymphoid organs and, most importantly, protecting the airway barrier from virus-induced cytopathology.”
lebonheur.org/news/antivira...
Cells. Research Paper: